Lucid Diligence Brief: Mirum to acquire Bluejay Therapeutics
Lucid Diligence Brief: Mirum to acquire Bluejay Therapeutics Professional…
Lucid Diligence Brief: SciNeuro Pharmaceuticals $53M financing
Lucid Diligence Brief: SciNeuro Pharmaceuticals $53M financing Professional…
Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer Ventures
Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer…
Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy for lung cancer
Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy…
Lucid Diligence Brief: Waker BioScience Series A in CGT
Lucid Diligence Brief: Waker BioScience Series A in CGT Professional audiences…
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+ Professional audiences…
Lucid Diligence Brief: Sword Health partners with Greece on AI health "front door"
Lucid Diligence Brief: Sword Health partners with Greece on AI health "front…
Lucid Diligence Brief: Neurogen Biomarking and Tasso partnership for at-home Alzheimer’s blood collection
Lucid Diligence Brief: Neurogen Biomarking and Tasso partnership for at-home…
Lucid Diligence Brief: WellBeam $10M Series A
Lucid Diligence Brief: WellBeam $10M Series A Professional audiences only. Not…
Lucid Diligence Brief: Abbott to acquire Exact Sciences
Lucid Diligence Brief: Abbott to acquire Exact Sciences Professional audiences…
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T deal
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T…
Lucid Diligence Brief: Avanzanite Bioscience €32m Series A
Lucid Diligence Brief: Avanzanite Bioscience €32m Series A Professional…

